ClinicalTrials.gov
public full text
Public Domain
Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation
In contrast with bisphosphonates,discontinuation of denosumab results in gradual loss of bone mineral density gains. The investigators aim to evaluate whether in patients treated with denosumab, a single zoledronic acid infusion would prevent the anticipated bone loss.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Data for "In silico exploration of osteoclast precursor inhibition for preventing rapid bone loss after denosumab discontinuation"#280735
- Data for "In silico exploration of osteoclast precursor inhibition for preventing rapid bone loss after denosumab discontinuation"#280730
- Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma#853499
- Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation#846070
- Mechanisms and management strategies for exacerbated bone loss following denosumab discontinuation.#439024
Record · ID 844032
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive